Santen today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the ...

An exclusive program uniting the top 12% of U.S. MiSight day prescribers to advance myopia management strategies.

The Nexperia case offers a sobering tale for the future of European technological competitiveness.

Over time, as the Bush administration sank into ignominy, Cheney’s influence waned. He left office one of its most reviled ...

The US launch of a myopia control spectacle lens, research into modifiable myopia risk factors, and atropine developments ...

How severe should myopia be in a pediatric patient to justify starting treatment, and when is it appropriate to begin tapering that treatment.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SYD-101 met its primary phase 3 efficacy endpoint, but ...

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

UAB School of Optometry professor is joining a national network study to research myopia prevention in children. Myopia, ...

As scientists try to untangle the reasons for skyrocketing rates of nearsightedness in kids, new treatment options can help prevent their vision from getting worse. In the U.S. myopia rates have ...

BARTOW, Fla. — The Polk County School District is hoping a new state-of-the-art program can help fill the need for air traffic controllers in the county and nationwide. The past few weeks have been ...

Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025 ...